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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand new pacemaker after implantation of the balloon-expandable Sapien prosthesis
(BES).
Methods: We analyzed 252 consecutive patients undergoing implantation of BES
without pre-existing pacemaker. All patients underwent pre-procedural CT assessment
of the aortic root. The congruence between annulus and valve prosthesis was assessed
using the area cover index (ACI): 100 x (prosthesis area - CT annulus area/ prosthesis
area). ECGs were performed at baseline, immediately after TAVI and at discharge.
Results: We divided the population in two groups according to median ACI value.
There were no differences in baseline characteristics except more women in the ACI
17% group compared to ACI < 17% group (67% vs. 33% p< 0.01). The QRS
interval duration immediately after TAVI and at discharge, incidence of new LBBB
and of new pacemaker was signiﬁcantly higher in ACI 17% group (Figure).OUTCOME ACCORDING TO VARC-2 DEFINITIONS
n/1904 (%)
Device insuccess 221 (11.6)
>1 valve implanted 14 (0.7)
Aortic valve replacement 9 (0.5)
Operative mortality (within 24h) 47 (2.5)
Aortic regurgitation  moderate 100 (5.2)
Mean aortic gradient  20 mmHg 64 (3.4)
Acute Myocardial Infarction ( 72 h) 26 (1.4)
Stroke (non disabling) 36 (1.9)
Stroke (disabling) 18 (1.0)
Life threatening bleeding 186 (9.9)
Major bleeding 200 (10.6)
Major vascular complication 177 (9.3)
Acute Kidney Injury (AKIN) grade 2-3 155 (8.1)
PM implantation (before discharge) 116 (6.1)Conclusions: PO of 17% is associated with increased risk of conduction abnor-
malities and need for new pacemaker after implantation of balloon-expandable Sapien
prosthesis.
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Background: Encouraging results have been demonstrated for TAVI in patients with
reduced left ventricular (LV) ejection fraction (LVEF). Not all patients with systolic
LV dysfunction may proﬁt from TAVI to the same extent, however. The largest
beneﬁt is typically observed in patients who demonstrate LV function (LVF) recovery
after valve intervention. Aim of this study was to identify predictors of LVF recovery
(absolute increase in LVEF of 10%) at mid-term follow-up after TAVI in patients
with preoperative moderate to severe LV dysfunction (LVEF40%).
Methods: Six international TAVI centers participated in this multicenter retrospective
registry. All patients with LVEF40% who underwent TAVI for symptomatic severe
aortic valve stenosis (AS) were identiﬁed in local institutional databases. Baseline,
procedural and follow-up clinical data and echocardiographic images were reviewed
for relevant data.
Results: Between November 2005 and July 2013, 1497 patients underwent TAVI for
symptomatic AS, of which 253 (17%) had a LVEF40%. Eventually, 150 (60%)
patients (mean age 78.68.2 years, 62% male) were included in the study, as 103
(40%) patients lacked echocardiographic mid-term follow-up or underwent interfering
resynchronization therapy. There were no signiﬁcant baseline differences between
included and excluded patients. TAVI was mainly performed through transfemoral
(85%) or transapical (11%) approach with an Edwards SAPIEN (37%) or Medtronic
CoreValve (63%) device. At mid-term follow-up, 67 (45%) patients demonstrated
LVF improvement. Previous CABG (OR¼0.21, CI 95% 0.07-0.60, p¼0.004),
absence of concentric remodeling (OR¼0.35, CI 95% 0.15-0.84, p¼0.019) and pre-
operative left bundle branch block (OR¼0.35, CI 95% 0.13-0.98, p¼0.047) were
independently associated with a reduced likelihood of LVF improvement; higher
preoperative mean gradient (OR¼1.04, CI 95% 1.01-1.07, p¼0.018) with an
increased likelihood of LVF improvement.
Conclusions: Previous CABG, absence of concentric remodeling, and preoperative
LBBB are negatively associated, while higher mean gradient is positively associated
with LVF improvement after TAVI in patients with preoperative moderate to severe
LV dysfunction.
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Background: Transcatheter aortic valve implantation (TAVI) has been proposed as a
therapeutic option for high risk or inoperable patients with severe symptomatic aortic
valve stenosis. aim of this retrospective multicenter study is to report early and mid-
term clinical and echocardiographic outcomes of patients undergoing TAVI with a
balloon-expandable device in Italy
Methods: From 2007 through 2012, 1904 patients were enrolled at 33 centers in the
Italian Transcatheter balloon-Expandable valve Registry (ITER). The study device is
the Sapien/Sapien XT prosthesis (Edwards Lifescience, Irvine, USA). A minimum
follow-up of one-year was required to be part of the Registry. Outcomes were
assigned according to the updated Valve Academic Research Consortium (VARC-2)
deﬁnitions.
Results: Mean age was 81.66.2 and 1147 (60.2%) patients were female. Out of 352
(18.5%) patients who had at least one previous cardiac intervention, 49 (2.6%) un-
derwent Valve-in-Valve TAVI. Mean Logistic EuroSCORE, EuroSCORE II and STS
Score were 22.414.6%, 7.36.7% and 9.27.6%, respectively. The procedural
accesses were: transfemoral, 1252 (65.8%); transapical (33.0%), 629; transaortic
(1.0%), 19; transaxillary (0.2%), 4. Thirty Day mortality was 7.2% (137 patients). The
most signiﬁcant VARC-2 outcomes are summarized in the table below. At discharge
mean transprosthetic gradient was 10.74.5 mmHg. Incidence of post-operative mild,
moderate or severe paravalvular leaks was respectively: 32.1%, 5.0% and 0.4%.
Overall 1, 2 and 3 years survival was 84.5%, 76.4 and 68.2%, respectively.Conclusions: According to our data, patients undergoing TAVI with a balloon
expandable device show good early and mid-term clinical and hemodynamic out-
comes. In particular the incidence of postoperative pace-maker implantation as well as
moderate/severe regurgitation seems reasonable. The incidence of mild regurgitation
is still a matter of concern.
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